Abdominal Aort Anevrizması ve EPHX2 Geni K55R Polimorfizmi
Öz
Amaç: Epoksieikozatrienoik asitler
(EET'ler), kalp damar sistemi üzerinde, arteriyel vazorelaksasyonu uyarma, kan
basıncını düşürme, antiinflamatuvar etkiler gibi çeşitli faydalı etkilere
sahiptir. EPHX2 geni tarafından kodlanan çözünür epoksit hidrolaz (çEH)
EET'leri daha az biyoaktif diollere dönüştürür. çEH inhibisyonunun,
abdominal aort anevrizmasının (AAA) da dahil olduğu birçok kardiyovasküler
hastalığa ait hayvan modellerinde pozitif etki oluşturduğu gösterilmiştir. çEH
aktivitesinde bir artışa neden olan EPHX2
genindeki K55R polimorfizminin koroner arter hastalığı, iskemik inme gelişimi
ile ilişkilendirilmiştir. Bununla birlikte, K55R polimorfizminin AAA ile
ilişkili olup olmadığı bilinmemektedir. Bu nedenle, bu çalışmanın amacı AAA ve EPHX2 K55R polimorfizmi arasındaki
ilişkinin incelenmesidir.
Gereç
ve Yöntem: Bu çalışmada, 75 sağlıklı ve 50 AAA hastasında K55R
polimorfizmi analiz edildi. K55R polimorfizminin genotiplenmesi, çift boya
hidroliz probları kullanılarak gerçek zamanlı PCR ile gerçekleştirildi.
Bulgular: Hasta ve kontrol grubu arasında
K55R polimorfizminin genotip dağılımları yönünden anlamlı bir fark saptanmadı.
Ayrıca, K55R polimorfizmi için heterozigot genotip taşıyan bireylerde AAA
gelişme riskinin yabanil tip allel taşıyan bireylere göre 1.63 kat daha yüksek
olduğu tespit edildi, ancak bu sonuç istatistiksel olarak anlamlı değere
ulaşmamıştır.
Sonuç: Sonuç olarak, heterozigot bireyler
1.63
kat daha yüksek AAA gelişimi için
risk oranına sahip olmalarına rağmen, istatistiksel sonuçlar bir Türk
popülasyonundaEPHX2 K55R polimorfizmi
ile AAA arasında bir ilişki olmadığını göstermiştir. Bununla
birlikte, bu polimorfizm ve AAA arasındaki ilişkiyi değerlendirmek için daha
fazla birey ve/veya farklı kökenleri içeren çeşitli popülasyonlarda ilave çalışmalara ihtiyaç
vardır.
Anahtar Kelimeler
Epoksieikozatrienoik asit abdominal aort anevrizması çözünür epoksit hidrolaz polimorfizm
Kaynakça
- 1. Steinberg CR, Morton A, Steinberg I. Measurement of the abdominal aortic after intravenous aortography in health and arteriosclerotic peripheral vascular disease. AJR 1965;95:703-8.
- 2. Daugherty A, Cassis LA. Mouse Models of Abdominal Aortic Aneurysms. Arterioscler Thromb Vasc Biol. 2004;24:429–34.
- 3. Weintraub NL. Understanding abdominal aortic aneurysm. N Engl J Med 2009;361: 1114–1116. 2.
- 4. Ali H, Alam S, Zafar F, Bushra R, Saleem S, Israr F, et al. Drug Utilization Pattern of Ciprofloxacin, Meropenem and Amikacin in Tertiary Care Hospital in Pakistan. Indian Journal of Pharmaceutical Sciences 2018; 80, 610-618.
- 5. Assar AN, Zarins CK. Ruptured abdominal aortic aneurysm: A surgical emergency with many clinical presentations. PostgradMed J 2009; 85: 268 - 73.
- 6. Brown PM, Pattenden R, Vernooy C, Zelt DT, Gutelius JR. Selective management of abdominal aortic aneurysms in a prospective measurement program. J VascSurg. 1996; 23: 213–20.
- 7. Moll FL, Powell JT, Fraedrich G, Verzini F, Haulon S, Waltham M, et al. Management of Abdominal Aortic Aneurysms Clinical Practice Guidelines of the European Society for Vascular Surgery. Eur J Vasc Endovasc Surg. 2011;41:1–58.
- 8. Kadoglou NP, Liapis CD. Matrix metalloproteinases: contribution to pathogenesis, diagnosis, surveillance and treatment of abdominal aortic aneurysms. Curr Med Res Opin. 2004; 20: 419-432.
- 9. Choke E, Cockerill G, Wilson WR, Sayed S, Dawson J, Loftus I, et al. A review of biological factors implicated in abdominal aortic aneurysm rupture. Eur J Vasc Endovasc Surg . 2005; 30:227-244.
- 10. Thompson MM, Jones L, Nasim A, Sayers RD, Bell PR. Angiogenesis in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg. 1996;11: 464-469.
- 11. Luria A, Bettaieb A, Xi Y, Shieh GJ, Liu HC, Inoue H, Tsai HJ, Imig JD, Haj FG, Hammock BD. Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance. Proc Natl Acad Sci 2011;108:9038–43.
- 12. Xu X, Zhao CX, Wang L, Tu L, Fang X, Zheng C, Edin ML, Zeldin DC, Wang DW. Increased CYP2J3 expression reduces insulin resistance in fructose-treated rats and db/db mice. Diabetes 2010;59:997–1005
- 13. Aliwarga T, Evangelista E, Sotoodehnia N, Lemaitre R, Totah R. Regulation of CYP2J2 and EET levels in cardiac disease and diabetes. International journal of molecular sciences 2018; 19: 1916.
- 14. Dai N, Zhao C, Kong Q, Li D, Cai Z, Wang M. Vascular repair and antiinflammatory effects of soluble epoxide hydrolase inhibitor. Experimental and therapeutic medicine. 2019; 17: 3580-3588.
- 15. Gurung AB, Mayengbam B, Bhattacharjee A. Discovery of novel drug candidates for inhibition of soluble epoxide hydrolase of arachidonic acid cascade pathway implicated in atherosclerosis. Computational biology and chemistry. 2018; 74, 1-11.
- 16. Xu X, Li R, Chen G, Hoopes SL, Zeldin DC, Wang DW. The role of cytochrome P450 epoxygenases, soluble epoxide hydrolase, and epoxyeicosatrienoic acids in metabolic diseases. Adv Nutr. 2016; 7:1122–8
- 17. Campbell WB, Imig JD, Schmitz JM, Falck JR. Orally Active Epoxyeicosatrienoic Acid Analogs. J Cardiovasc Pharmacol. 2017;70:211–224.
- 18. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, Liao JK. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999; 285: 1276–1279.
- 19. Pozzi A, Macias-Perez I, Abair T, Wei S, Su Y, Zent R, Falck JR, Capdevila JH. Characterization of 5,6- and 8,9-epoxyeicosatrienoic acids (5,6- and 8,9-EET) as potent in vivo angiogenic lipids. J. Biol. Chem. 2005; 280; 27138–27146.
- 20. Campbell WB, Fleming I. Epoxyeicosatrienoic acids and endothelium-dependent responses. Pflugers Arch. Eur. J. Physiol. 2010; 459: 881–895.
- 21. Yang L, Maki-Petaja K, Cheriyan J, McEniery C, Wilkinson IB. The role of epoxyeicosatrienoic acids in the cardiovascular system. Br. J. Clin. Pharmacol. 2015; 80: 28–44.
- 22. Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nature Reviews. Drug Discovery. 2009; 8:794–805.
- 23. Bellien J, Joannides R. Epoxyeicosatrienoic acid pathway in human health and diseases. Journal of Cardiovascular Pharmacology. 2013; 61:188–196.
- 24. Imig JD. Epoxides and soluble epoxide hydrolase in cardiovascular physiology. Physiological Reviews. 2012; 92:101–130.
- 25.Przybyla-Zawislak BD, Srivastava PK, Vazquez-Matias J, Mohrenweiser HW, Maxwell JE, Hammock BD, et al. Polymorphisms in human soluble epoxide hydrolase. Mol Pharmacol. 2003; 64: 482–490
- 26. Zhang L, Ding H, Yan J, Hui R, Wang W, Kissling GE, Zeldin DC, Wang DW. Genetic variation in cytochrome P450 2J2 and soluble epoxide hydrolase and risk of ischemic stroke in a Chinese population. Pharmacogenet Genomics 2008; 18: 45–51.
- 27. Lee J, Dahl M, Grande, P, Tybjaerg-Hansen A, Nordestgaard BG. Genetically reduced soluble epoxide hydrolase activity and risk of stroke and other cardiovascular disease. Stroke 2010; 41(1): 27-33.
- 28. Lee CR, Pretorius M, Schuck RN, Burch LH, Bartlett J, Williams SM, Zeldin DC, Brown NJ. Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with forearm vasodilator responses in humans. Hypertension 2011; 57(1): 116-22.
- 29. Zhang LN, Vincelette J, Cheng Y, et al. Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation, and dyslipidemia. Arteriosclerosis,thrombosis, and vascular biology. 2009;29:1265-1270.
- 30 Kobeissi E, Hibino M, Pan H, Aune D. Blood pressure, hypertension and the risk of abdominal aortic aneurysms: a systematic review and meta-analysis of cohort studies. European Journal of Epidemiology 2019; 34: 6 547-555.
- 31.Decker M, Arand M, Cronin A. Mammalian epoxide hydrolases in xenobiyotic metabolism and signalling. Arch Toxicol. 2009; 83: 297–318.
- 32.Zordoky BNM, El-Kadi AOS. Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. Pharmacology & Therapeutics 2010; 125: 446–463.
- 33. Fava C, Montagnana M, Danese E et al. Homozygosity for the EPHX2 K55R polymorphism increases the long-term risk of ischemic stroke in men: a study in Swedes. Pharmacogenet Genomics 2010;20:94-103
- 34. Oni-Orisan A, Cresci S, Jones PG, Theken KN, Spertus JA, Lee CR. Association between the EPHX2 p. Lys55Arg polymorphism and prognosis following an acute coronary syndrome. Prostaglandins & other lipid mediators 2018; 138, 15-22.
- 35. Gschwendtner A, Ripke S, Freilinger T, Lichtner P, Müller-Myhsok B, Wichmann HE, et al. Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with an increased risk of ischemic stroke in white Europeans Stroke 2008; 39, 1593-1596.
- 36. Kullmann S, Binner P, Rackebrandt K et al. Variation in the human soluble epoxide hydrolase gene and risk of restenosis after percutaneous coronary intervention. BMC Cardiovasc Disord 2009;9:48
- 37. Wutzler A, Kestler C, Perrot A et al. Variations in the human soluble epoxide hydrolase gene and recurrence of atrial fibrillation after catheter ablation. Int J Cardiol 2013;168:3647-51
- 38. Lee CR, North KE, Bray MS et al. Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. Hum Mol Genet 2006;15:1640-9.